Raja B Khan1, Arzu Onar. 1. Division of Neurology and Neuro-Oncology, St. Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105-2794, U.S.A. raja.khan@stjude.org
Abstract
PURPOSE: To study seizure outcome after antiepilepsy drug (AED) withdrawal in brain tumor patients and to analyze risk factors for seizure recurrence. METHODS: Brain tumor patients with seizures and at least one attempt at AED discontinuation were identified from the hospital database and neurology clinic records. After defining study variables, patient charts were abstracted for clinical and demographic data. Statistical analyses used log-rank tests and multivariable Cox proportional hazards models. RESULTS: Sixty-two patients discontinued AEDs at a median time of 5.6 years from the first seizure (range, 1.2-19.6 years). Median time since AED withdrawal was 2.3 years (range, 0.4-15.1 years). Seizures recurred in 17 (27%) patients within a median time of 0.8 years (range, 0.06-7.7 years). Median seizure-free period before AED withdrawal was 1.3 years (range, 0.1-11 years). More than one tumor resection and whole-brain radiation treatment (WBRT) were associated with seizure recurrence, whereas posterior fossa tumor location was correlated with reduced seizure recurrence risk. At seizure recurrence, control was easily reestablished in 10 patients with AED reinstitution and after dose adjustment in five; two patients with poor drug compliance continue to have seizures. In 48 patients who had an EEG before AED withdrawal, spikes or slow waves did not correlate with seizure recurrence. CONCLUSIONS: AED withdrawal can be successfully achieved in majority of carefully selected patients. WBRT and multiple tumor resections seem to be associated with an increased hazard for seizure recurrence.
PURPOSE: To study seizure outcome after antiepilepsy drug (AED) withdrawal in brain tumorpatients and to analyze risk factors for seizure recurrence. METHODS:Brain tumorpatients with seizures and at least one attempt at AED discontinuation were identified from the hospital database and neurology clinic records. After defining study variables, patient charts were abstracted for clinical and demographic data. Statistical analyses used log-rank tests and multivariable Cox proportional hazards models. RESULTS: Sixty-two patients discontinued AEDs at a median time of 5.6 years from the first seizure (range, 1.2-19.6 years). Median time since AED withdrawal was 2.3 years (range, 0.4-15.1 years). Seizures recurred in 17 (27%) patients within a median time of 0.8 years (range, 0.06-7.7 years). Median seizure-free period before AED withdrawal was 1.3 years (range, 0.1-11 years). More than one tumor resection and whole-brain radiation treatment (WBRT) were associated with seizure recurrence, whereas posterior fossa tumor location was correlated with reduced seizure recurrence risk. At seizure recurrence, control was easily reestablished in 10 patients with AED reinstitution and after dose adjustment in five; two patients with poor drug compliance continue to have seizures. In 48 patients who had an EEG before AED withdrawal, spikes or slow waves did not correlate with seizure recurrence. CONCLUSIONS:AED withdrawal can be successfully achieved in majority of carefully selected patients. WBRT and multiple tumor resections seem to be associated with an increased hazard for seizure recurrence.
Authors: Rohit R Das; Elinor Artsy; Shelley Hurwitz; Patrick Y Wen; Peter Black; Alexandra Golby; Barbara Dworetzky; Jong Woo Lee Journal: J Neurooncol Date: 2012-01-03 Impact factor: 4.130
Authors: Johan A F Koekkoek; Melissa Kerkhof; Linda Dirven; Jan J Heimans; Jaap C Reijneveld; Martin J B Taphoorn Journal: Neuro Oncol Date: 2015-03-25 Impact factor: 12.300
Authors: Johan A F Koekkoek; Melissa Kerkhof; Linda Dirven; Jan J Heimans; Tjeerd J Postma; Maaike J Vos; Jacoline E C Bromberg; Martin J van den Bent; Jaap C Reijneveld; Martin J B Taphoorn Journal: BMC Neurol Date: 2014-08-15 Impact factor: 2.474
Authors: Pim B van der Meer; Linda Dirven; Martin J van den Bent; Matthias Preusser; Martin J B Taphoorn; Roberta Rudá; Johan A F Koekkoek Journal: Neurooncol Pract Date: 2021-10-21